Orphan Drugs To Make Up 16% Of Rx Market By 2018, Says Evaluate Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
The health care consultancy released a report that shows the rapid growth of the orphan drug sector as companies take advantage of incentives. Orphan oncologic drugs dominate the market, and Novartis is slated to lead in orphan sales by 2018.
You may also be interested in...
Regulatory Freelancing: Rare Disease Group Hopes To Shape FDA Guidance
EveryLife Foundation is working on a white paper that it hopes will inform FDA’s guidance clarifying accelerated approval and fast track pathways, which is mandated in FDASIA.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.